Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong et al. (Fri,) studied this question.

www.synapsesocial.com/papers/6a008703831589f3542dd968 — DOI: https://doi.org/10.1158/1078-0432.ccr-16-2554

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Somatic mutations affect key pathways in lung adenocarcinoma· 2008 · 2,734 citations
2. <i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis· 2016 · 1,227 citations
3. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy· 2016 · 89 citations
4. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment· 2016 · 88 citations
5. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer· 2016 · 383 citations